Printer Friendly

Lion TCR announces USD20m from Series A financing round.

M2 PHARMA-May 28, 2018-Lion TCR announces USD20m from Series A financing round

(C)2018 M2 COMMUNICATIONS

Singapore biotech company Lion TCR Pte Ltd reported on Sunday the receipt of USD20m under its Series A financing round.

The Series A financing round was led primarily by undisclosed existing investors as well as other new investors: Yashang Capital and Westlake Ventures Capital.

Proceeds from this fundraising will be used by Lion TCR Pte Ltd to advance its on-going clinical trials of its lead candidate LioCyx (personalized HBV specific TCR T cell therapy against HCC) in major hospitals in China and Singapore, as well as for broadening its products pipeline to fight viral-related solid tumors and clearance of chronic hepatitis B.

Hepatocellular carcinoma (HCC) has over 700,000 new cases every year, the world second deadly cancer, of which 80% in Asia Pacific and 50% in China.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 28, 2018
Words:155
Previous Article:Luye Pharma closes acquisition of signature products Seroquel and Seroquel XR.
Next Article:Indivior updates the regulatory submission of SUBLOCADE Injection for opioid dependence in Australia.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters